{"id":2583,"date":"2021-01-27T04:34:07","date_gmt":"2021-01-27T02:34:07","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2583"},"modified":"2021-01-27T04:34:10","modified_gmt":"2021-01-27T02:34:10","slug":"la-revista-science-confirma-la-potente-actividad-de-aplidin-de-pharmamar-frente-al-covid","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2583","title":{"rendered":"La revista &#8216;Science&#8217; confirma la potente actividad de Aplidin de PharmaMar frente al COVID"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Un estudio en ratones muestra que Aplidin (plitidepsina) de PharmaMar reduce la replicaci\u00f3n viral, lo que provoca una disminuci\u00f3n del 99% de las cargas virales del SARS-CoV-2 en los pulmones de los animales tratados.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharmaMar<\/strong>\u00a0ha anunciado este martes la publicaci\u00f3n del art\u00edculo de investigaci\u00f3n titulado \u201dPlitidepsin has potent preclinical efficacy against\u00a0<strong>SARS-CoV-2<\/strong>\u00a0by targeting the host protein eEF1A\u201d (<strong>Plitidepsina<\/strong>\u00a0tiene una potente eficacia precl\u00ednica contra el SARS-CoV-2 al dirigirse a la prote\u00edna del hu\u00e9sped eEF1A) en la revista cient\u00edfica Science. <\/p>\n\n\n\n<figure class=\"wp-block-image size-medium is-resized is-style-rounded\"><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1.jpg\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1-300x141.jpg\" alt=\"\" class=\"wp-image-2585\" width=\"448\" height=\"210\" srcset=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1-300x141.jpg 300w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1-1024x482.jpg 1024w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1-768x362.jpg 768w, https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/caso-exito-pharmamar-cabecera-1200x565-1.jpg 1200w\" sizes=\"auto, (max-width: 448px) 100vw, 448px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">La publicaci\u00f3n concluye que plitidepsina act\u00faa bloqueando la prote\u00edna eEF1A, presente en las c\u00e9lulas humanas, y que es utilizada por el SARS-CoV-2 para<br>reproducirse e infectar a otras c\u00e9lulas. Este mecanismo culmina en una eficacia antiviral in vivo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Esta publicaci\u00f3n ha sido fruto de la colaboraci\u00f3n entre PharmaMar y los laboratorios de<strong>\u00a0Kris White, Adolfo Garc\u00eda-Sastre y Thomas Zwaka<\/strong>, en los Departamentos de Microbiolog\u00eda y de Biolog\u00eda Celular, Regenerativa y del Desarrollo, en la Icahn School of Medicine; de Kevan Shokat y Nevan Krogan, en el Instituto de Biociencias Cuantitativas de la\u00a0<strong>Universidad de California San Francisco<\/strong>, y de\u00a0<strong>Marco Vignuzzi<\/strong>\u00a0en el<strong>\u00a0Instituto Pasteur de Par\u00eds<\/strong>. <\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Los autores concluyen que plitidepsina es, con diferencia, el compuesto m\u00e1s potente y deber\u00eda probarse en ensayos cl\u00ednicos ampliados para el tratamiento de COVID-19.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El documento tambi\u00e9n afirma que, aunque la<strong>\u00a0toxicidad<\/strong>\u00a0es una preocupaci\u00f3n en cualquier antiviral dirigido a una prote\u00edna de la c\u00e9lula humana, el perfil de seguridad de plitidepsina est\u00e1 bien establecido en humanos y, que las\u00a0<strong>dosis bien toleradas<\/strong>\u00a0de plitidepsina utilizadas en el ensayo cl\u00ednico Covid-19, son significativamente m\u00e1s bajas que las utilizadas en estos experimentos.<\/p>\n\n\n\n<p class=\"has-vivid-purple-color has-text-color has-large-font-size wp-block-paragraph\">Actualmente, PharmaMar est\u00e1 negociando con diferentes organismos reguladores el inicio de los ensayos de fase III previstos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">M\u00e1s informaci\u00f3n en Comunicado de prensa de <a href=\"https:\/\/pharmamar.com\/wp-content\/uploads\/2021\/01\/NdPScience_plitidepsina_PhM_DEF.pdf\">PharmaMar<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudio en ratones muestra que Aplidin (plitidepsina) de PharmaMar reduce la replicaci\u00f3n viral, lo que provoca una disminuci\u00f3n del 99% de las cargas virales del SARS-CoV-2 en los pulmones de los animales tratados. PharmaMar\u00a0ha anunciado este martes la publicaci\u00f3n del art\u00edculo de investigaci\u00f3n titulado \u201dPlitidepsin has potent preclinical efficacy against\u00a0SARS-CoV-2\u00a0by targeting the host protein [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2584,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[4,11,6,79],"tags":[81,66],"class_list":["post-2583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-espana","category-galicia","category-investigacion","category-medicacion","tag-covid","tag-medicacion"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>La revista &#039;Science&#039; confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2583\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"La revista &#039;Science&#039; confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"Un estudio en ratones muestra que Aplidin (plitidepsina) de PharmaMar reduce la replicaci\u00f3n viral, lo que provoca una disminuci\u00f3n del 99% de las cargas virales del SARS-CoV-2 en los pulmones de los animales tratados. PharmaMar\u00a0ha anunciado este martes la publicaci\u00f3n del art\u00edculo de investigaci\u00f3n titulado \u201dPlitidepsin has potent preclinical efficacy against\u00a0SARS-CoV-2\u00a0by targeting the host protein [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2583\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2021-01-27T02:34:07+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2021-01-27T02:34:10+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"440\" \/>\r\n\t<meta property=\"og:image:height\" content=\"430\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"La revista &#8216;Science&#8217; confirma la potente actividad de Aplidin de PharmaMar frente al COVID\",\"datePublished\":\"2021-01-27T02:34:07+00:00\",\"dateModified\":\"2021-01-27T02:34:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg\",\"keywords\":[\"covid\",\"medicaci\u00f3n\"],\"articleSection\":[\"En Espa\u00f1a\",\"Galicia\",\"Investigaci\u00f3n\",\"medicaci\u00f3n\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2583#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2583\",\"name\":\"La revista 'Science' confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg\",\"datePublished\":\"2021-01-27T02:34:07+00:00\",\"dateModified\":\"2021-01-27T02:34:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2583\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#primaryimage\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg\",\"width\":440,\"height\":430,\"caption\":\"La plitidepsina es un compuesto qu\u00edmico extra\u00eddo de la ascidia Aplidium albicans\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2583#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La revista &#8216;Science&#8217; confirma la potente actividad de Aplidin de PharmaMar frente al COVID\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La revista 'Science' confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2583","og_locale":"es_ES","og_type":"article","og_title":"La revista 'Science' confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus","og_description":"Un estudio en ratones muestra que Aplidin (plitidepsina) de PharmaMar reduce la replicaci\u00f3n viral, lo que provoca una disminuci\u00f3n del 99% de las cargas virales del SARS-CoV-2 en los pulmones de los animales tratados. PharmaMar\u00a0ha anunciado este martes la publicaci\u00f3n del art\u00edculo de investigaci\u00f3n titulado \u201dPlitidepsin has potent preclinical efficacy against\u00a0SARS-CoV-2\u00a0by targeting the host protein [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2583","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2021-01-27T02:34:07+00:00","article_modified_time":"2021-01-27T02:34:10+00:00","og_image":[{"width":440,"height":430,"url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg","type":"image\/jpeg"}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2583#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2583"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"La revista &#8216;Science&#8217; confirma la potente actividad de Aplidin de PharmaMar frente al COVID","datePublished":"2021-01-27T02:34:07+00:00","dateModified":"2021-01-27T02:34:10+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2583"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2583#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg","keywords":["covid","medicaci\u00f3n"],"articleSection":["En Espa\u00f1a","Galicia","Investigaci\u00f3n","medicaci\u00f3n"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2583#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2583","url":"https:\/\/lupusgalicia.org\/?p=2583","name":"La revista 'Science' confirma la potente actividad de Aplidin de PharmaMar frente al COVID - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2583#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2583#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg","datePublished":"2021-01-27T02:34:07+00:00","dateModified":"2021-01-27T02:34:10+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2583#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2583"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2583#primaryimage","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/440px-Cionaintestinalis.jpg","width":440,"height":430,"caption":"La plitidepsina es un compuesto qu\u00edmico extra\u00eddo de la ascidia Aplidium albicans"},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2583#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"La revista &#8216;Science&#8217; confirma la potente actividad de Aplidin de PharmaMar frente al COVID"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2583"}],"version-history":[{"count":1,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2583\/revisions"}],"predecessor-version":[{"id":2586,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2583\/revisions\/2586"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/media\/2584"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}